Journal article
Formulary Drug Review: Ocrelizumab
Hospital pharmacy (Philadelphia), Vol.52(9), pp.599-606
10/2017
Handle:
https://hdl.handle.net/2376/113553
PMCID: PMC5735732
PMID: 29276296
Abstract
Each month, subscribers to
The Formulary Monograph Service
receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are available online to subscribers. Monographs can be customized to meet the needs of a facility. Through the cooperation of
The Formulary, Hospital Pharmacy
publishes selected reviews in this column. For more information about
The Formulary Monograph Service
, contact Wolters Kluwer customer service at 866-397-3433.
Metrics
19 Record Views
Details
- Title
- Formulary Drug Review: Ocrelizumab
- Creators
- Zaynah K Ali - Washington State University, Spokane, USADanial E Baker - Washington State University, Spokane, USA
- Publication Details
- Hospital pharmacy (Philadelphia), Vol.52(9), pp.599-606
- Academic Unit
- Pharmacotherapy, Department of
- Publisher
- SAGE Publications; Sage CA: Los Angeles, CA
- Identifiers
- 99900547683201842
- Language
- English
- Resource Type
- Journal article